PaxMedica Inc

PaxMedica, Inc. is an early clinical stage biopharmaceutical company. It focuses on the development of anti-purinergic therapies for the treatment of neurodevelopmental disorders, including autism spectrum disorder and Fragile X syndrome tremor-ataxia. The company was founded in April 5, 2018 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.

PaxMedica Secures Immediate Exercise of Warrants

Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home.

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) ( OTC:PXMD ), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica's recent achievements and ongoing actions to regain compliance with all applicable requirements for continued listing. PaxMedica has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal, working with the consulting firm that interacted previously with the Hearings Panel.

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east Africa. The request seeks emergency access to the Company's recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region.

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN --  PaxMedica , Inc. (NASDAQ:  PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

Beneficient

Trio Petroleum Corp

Penny stocks represent an exciting opportunity for investors looking to expand their portfolios with potentially lucrative, yet cost-effective options. Typically trading below five dollars per share, these stocks offer a gateway into investing with a smaller upfront financial commitment.

Choosing Unknown Penny Stocks, 3 Top Tips

PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.

Why is PaxMedica (PXMD) stock surging today?

PaxMedica (NASDAQ: PXMD ) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company reached a key milestone in drug development. The big news here is the company securing three pivotal registration/validation batches of PAX-101.

Why Is PaxMedica (PXMD) Stock Up 93% Today?

TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), which is currently planned for Q4 2024, and for the potential commercial availability in the U.S. of the first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei rhodesiense, a fatal, neglected tropical disease, if approved by the FDA.

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica's strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community.

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman and CEO. Overview: In this comprehensive company update video, Mr.

PaxMedica Releases Fireside Chat Video with CEO Howard Weisman

TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the closing of its previously announced public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $1.30 per share, are exercisable immediately upon issuance, and will expire five years after the initial exercise date.

PaxMedica Announces Closing of $7.0 Million Public Offering

Heart Test Laboratories Inc

Marpai

Signing Day Sports Inc

Tempest Therapeutics

Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price changes and explosive short-term gains.

Penny Stocks To Buy? 5 To Watch Right Now

PaxMedica (NASDAQ: PXMD ) stock is climbing higher on Wednesday after the company completed a public offering for its shares. According to a press release from the company, it's offering 5,384,615 shares of PXMD stock at a price of $1.30 per share.

Why Is PaxMedica (PXMD) Stock Up 57% Today?

PaxMedica (NASDAQ: PXMD ) stock is cratering today after the company announced a $7 million public offering. The offering consists of 5.38 million shares and warrants to purchase up to 5.38 million shares.

Why Is PaxMedica (PXMD) Stock Down 40% Today?

TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $1.30 per share, will be exercisable immediately upon issuance, and will expire five years after the initial exercise date.

PaxMedica Announces Pricing of $7.0 Million Public Offering

LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers PaxMedica's recent announcement of the completion of a type-B meeting with the FDA. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated.

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive business update along with its financial results for the third quarter ended September 30, 2023. Key Updates and Achievements Successfully concluded a crucial FDA Type-B meeting, gathering vital guidance for the NDA submission of PAX-101.

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

PaxMedica (NASDAQ: PXMD ) stock is rising higher on Tuesday as investors celebrate the company's publication of Phase 2 clinical trial results. The study was published in the Annals of General Psychiatry and focused on the use of low-dose suramin intravenous infusions as a treatment for Autism Spectrum Disorder (ASD).

Why Is PaxMedica (PXMD) Stock Up 95% Today?

Matinas BioPharma Hlds

NanoVibronix

Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.

Penny Stocks To Buy Now? 3 to Watch With Big News

TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the Annals of General Psychiatry. The research, led by Chief Medical Officer Dr. David Hough, along with a team of renowned co-authors specializing in Autism Spectrum Disorder (ASD), the research explores the potential of low-dose suramin intravenous infusions as an ASD treatment.

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- via IBN --  PaxMedica, Inc. (Nasdaq: PXMD ), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has engaged Bourne Partners , a leading financial services firm specializing in the pharma, pharma services, and consumer health sectors. This marks an important step in PaxMedica's efforts to explore potential monetization of a Priority Review Voucher (PRV) prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness.

PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)

TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (Nasdaq: PXMD ), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease.

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that as a result of its 1-for-17 reverse stock split of its common stock that became effective at 8:03 a.m. Eastern Time on October 30, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market on October 31, 2023. PaxMedica's common stock will continue to trade under the existing trading symbol “PXMD.” The new CUSIP number for the common stock following the reverse stock split is 70424C 203.

PaxMedica Announces 1-for-17 Reverse Stock Split

PaxMedica (NASDAQ: PXMD ) stock is jumping significantly higher against the backdrop of another soft session on Wall Street. This morning, management announced a productive discussion with the U.S. Food and Drug Administration (FDA) over positive clinical trial results for a key drug.

News for PaxMedica Inc Stock (PXMD)